Breast cancer (BC) is the most common endocrine cancer and the second leading cause of cancer-related death in women. About 75% of BCs expresses high levels of estrogen receptors that sustain the tumor growth. Moreover, in BC estrogens prevent apoptosis induced by granzyme B released by cytotoxic T lymphocytes and NK cells through the production of the granzyme B inhibitor PI-9. As a consequence, cancer cells acquire the ability to escape immune surveillance’s signaling. Although some studies explored the role of PI-9 in BC cells, its presence has not been investigated in cancer stem cells so far. In this research, tertiary tumorspheres were obtained from estrogen receptor-alfa positive (ERalfa+) BC MCF7 cells and studies were performed to evaluate their stem identity. These tumorspheres showed high levels of stemness markers (Nanog, Oct3/4 and Sox2) and self-renewal ability. The exposure to estrogens (17-beta estradiol and genistein) increased the number and sizes of tumorspheres as well as the level of the proliferating cell nuclear antigen (PCNA). The analysis of the three isoforms (66, 46 and 36 kDa) of ERalfa disclosed that tertiary tumorspheres exhibit a marked increase in ERalfa36, while the level of ERalfa66, which is highly expressed in MCF7 cells, dropped. Then, we analyzed the granzyme B inhibitor PI-9, which is transcriptionally regulated by ERalfa66. Surprisingly, we found that tertiary tumorspheres express a higher level of both PI-9 protein and mRNA than MCF7 cells, despite the reduced level of ERalfa66. The high content of PI-9 might be ascribed to the activation of proliferative CXCR4/phospho-p38 axis which was observed only in tertiary tumorspheres. Taken together, these events could supply a selective advantage to BC stem cells by interfering with immune surveillance systems and open the way to new possible targets for BC treatment.

Lauricella, M., Carlisi, D., Giuliano, M., Calvaruso, G., Cernigliaro, C., D'Anneo A. (2015). Possible regulatory mechanisms responsible for the high expression of serpin protease inhibitor PI-9 in ER+ -derived breast cancer stem cells.. In Biotecnologie Ricerca di Base interdisciplinare traslazionale in ambito biomedico. 3 meeting IBIM-CNR-SteBicef-Unipa. (pp.46-47).

Possible regulatory mechanisms responsible for the high expression of serpin protease inhibitor PI-9 in ER+ -derived breast cancer stem cells.

LAURICELLA, Marianna;CARLISI, Daniela;GIULIANO, Michela;CALVARUSO, Giuseppe;CERNIGLIARO, CESARE;D'ANNEO, Antonella
2015-01-01

Abstract

Breast cancer (BC) is the most common endocrine cancer and the second leading cause of cancer-related death in women. About 75% of BCs expresses high levels of estrogen receptors that sustain the tumor growth. Moreover, in BC estrogens prevent apoptosis induced by granzyme B released by cytotoxic T lymphocytes and NK cells through the production of the granzyme B inhibitor PI-9. As a consequence, cancer cells acquire the ability to escape immune surveillance’s signaling. Although some studies explored the role of PI-9 in BC cells, its presence has not been investigated in cancer stem cells so far. In this research, tertiary tumorspheres were obtained from estrogen receptor-alfa positive (ERalfa+) BC MCF7 cells and studies were performed to evaluate their stem identity. These tumorspheres showed high levels of stemness markers (Nanog, Oct3/4 and Sox2) and self-renewal ability. The exposure to estrogens (17-beta estradiol and genistein) increased the number and sizes of tumorspheres as well as the level of the proliferating cell nuclear antigen (PCNA). The analysis of the three isoforms (66, 46 and 36 kDa) of ERalfa disclosed that tertiary tumorspheres exhibit a marked increase in ERalfa36, while the level of ERalfa66, which is highly expressed in MCF7 cells, dropped. Then, we analyzed the granzyme B inhibitor PI-9, which is transcriptionally regulated by ERalfa66. Surprisingly, we found that tertiary tumorspheres express a higher level of both PI-9 protein and mRNA than MCF7 cells, despite the reduced level of ERalfa66. The high content of PI-9 might be ascribed to the activation of proliferative CXCR4/phospho-p38 axis which was observed only in tertiary tumorspheres. Taken together, these events could supply a selective advantage to BC stem cells by interfering with immune surveillance systems and open the way to new possible targets for BC treatment.
dic-2015
3 meeting IBIM-CNR-SteBicef-Unipa. Biotecnologie Ricerca di Base interdisciplinare traslazionale in ambito biomedico.
Palermo
17-18 Dicembre 2015
3
2015
2015
2
Online
https://www.ibim.cnr.it/homebiotec
Lauricella, M., Carlisi, D., Giuliano, M., Calvaruso, G., Cernigliaro, C., D'Anneo A. (2015). Possible regulatory mechanisms responsible for the high expression of serpin protease inhibitor PI-9 in ER+ -derived breast cancer stem cells.. In Biotecnologie Ricerca di Base interdisciplinare traslazionale in ambito biomedico. 3 meeting IBIM-CNR-SteBicef-Unipa. (pp.46-47).
Proceedings (atti dei congressi)
Lauricella, M; Carlisi, D; Giuliano, M; Calvaruso, G; Cernigliaro, C; D'Anneo A.
File in questo prodotto:
File Dimensione Formato  
2015 Lauricella et al CNR Stebicef.pdf

accesso aperto

Descrizione: 2015 Lauricella et al CNR Stebicef
Dimensione 3.05 MB
Formato Adobe PDF
3.05 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/176078
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact